|
|
|
|||||
Archive:
| |||||
(December 18, 2001) -- In their quest to mass-produce an effective malaria vaccine, scientists might one day replace expensive manufacturing facilities with a goat. In a study reported December 18 in the Proceedings of the. (Science Daily)
Wanted: computers for a humanitarian cause Jul 21, 2006
The team originally wanted to predict the amount of protection afforded by a prototype malaria vaccine in order to decide how effective it must be before it is worth investing in ... They found from their modelling that the malaria vaccine being tested (GlaxoSmithKline's RTS,S jab) would be around one-third as effective in real life as it was in the controlled conditions of a clinical trial. (Nature News Service)
You don't have to be Buffett Jul 12, 2006
5 billion in major gifts has been given to the Global Alliance for Vaccines, United Negro College Fund and the Malaria Vaccine Initiative. Donations on that scale are rare, but all communities have their share of philanthropists. (Frederick News-Post)
Gates funds a revolution in health care Jul 5, 2006
Dr. Melinda Moree, head of the Malaria Vaccine Initiative, said the foundation is involved in every aspect of the programs it funds. The initiative is working on a vaccine for children with help from the Gates Foundation. (Herald Online, SC -- Health)
A new era for supercharged philanthropy Jun 28, 2006
Where the Rockefeller Foundation focused on vaccines for yellow fever, the Gates Foundation is supporting the quest for a malaria vaccine. America's 19th- century magnates didn't spawn foundations as large as the Gateses', even after adjusting for inflation. (Christian Science Monitor -- World)
Buffett Will Donate $30.7 Billion in Berkshire Stock to Gates Foundation Jun 27, 2006
5 billion to the Global Alliance for Vaccines, $1 billion to the United Negro College Fund and $258 million to the Malaria Vaccine Initiative. It gave away $1. (Bloomberg -- Canada)
Experts: Gates could put new face on philanthropy Jun 25, 2006
WASHINGTON - Melinda Moree met plenty of naysayers who dismissed the prospects of a malaria vaccine ... "Of course it is," Gates countered, according to Moree, now director of the PATH Malaria Vaccine Initiative in Seattle, which along with other groups has received nearly $500 million from the Bill da Gates Foundation to develop, test, manufacture and eventually distribute a malarial vaccine ... GlaxoSmithKline PLC conducted malaria vaccine trials on 2,000 children, and "that trial wouldn't... (Florida Today)
WP: Bill Gates world of possibility Jun 21, 2006
Melinda Moree met plenty of naysayers who dismissed the prospects of a malaria vaccine ... "Of course it is," Gates countered, according to Moree, now director of the PATH Malaria Vaccine Initiative in Seattle, which along with other groups has received nearly $500 million from the Bill and Melinda Gates Foundation to develop, test, manufacture and eventually distribute a malarial vaccine ... conducted malaria vaccine trials on 2,000 children, and "that trial wouldn't have taken place without... (MSNBC -- Race)
Study points to genes responsible for malaria parasite's survival in attempts to eradicate it Jun 20, 2006
"While millions of dollars have been spent to develop a malaria vaccine, we still don't have a licensed product," says Associate Professor Elizabeth Winzeler of Scripps Research, who led the study. "Our findings may help in the vaccine-development effort, because they point to novel immunogens that could be targeted.". (EurekAlert!)
Technology to charity Jun 16, 2006
Last year, for example, it earmarked $258 million for advanced development of a malaria vaccine to fight a disease that kills 2,000 African children every day. That's a strategic shift from the older model of philanthropy: Foundations would wait for drugs to be available, then pay for distribution, says Gene Tempel of the Center on Philanthropy at Indiana University. (USA Today -- Tech)
Mosquito Immune System: Same Immune Factors Used To Fight Malaria Parasite And Infectious Pathogens Jun 13, 2006
(January 20, 2005) -- In an innovative project with implications for malaria vaccine development, scientists have used genomics, proteomics and gene expression studies to trace how malaria parasites evolve on a molecular. . (Science Daily)
Boost To Vaccine Development: New Approach Provides Potent, Long-lasting Immunity May 25, 2006
(November 1, 2004) -- The results of a randomized controlled trial of a malaria vaccine called ME-TRAP are published this month in PLoS Medicine. "This first field efficacy trial was an important milestone in the ... > (October 21, 2005) -- Researchers at the University of Pennsylvania School of Medicine found that protective levels of immunity against pneumococcus could be obtained in immune-suppressed myeloma patients who were given a ... > (November 7, 2003) -- An innovative vaccine against... (Science Daily)
Drug delusions at the WHO May 20, 2006
The US government's attempt to develop a malaria vaccine in the early 1980s offers a salutary warning. This project absorbed millions of dollars and produced no results. (Bangkok Post)
Malaria venture stakeholders meet in Zambia May 6, 2006
The MMV stakeholders meeting follows the formation of the Malaria Clinical Trials Alliance (MCTA), announced on Africa Malaria Day on 25 April, which includes the MMV and PATH Malaria Vaccine Initiative, aiming to accelerate the research and development of vaccines and new and improved drugs targeting malaria. Medicines for Malaria Venture (MMV) is a non-profit organisation dedicated to reducing the burden of malaria in disease-endemic countries by discovering, developing and delivering new... (Panapress.com)
Phase III Clinical Trial with H5N1 Influenza Pandemic Vaccine May 5, 2006
The vaccine includes an adjuvant, similar to that used by GSK in the malaria vaccine that Hospital Clnic is testing in Mozambique, which enhances the immunogenic effects of the vaccine. The stimulation of the immune system caused by this adjuvant, has already proved successful as a part of a vaccine against conventional influenza, and permits to reduce the antigen concentration administered in each vaccination. (eMaxHealth.com)
PanAfrica:New Hope for Tackling an Old Scourge on Africa Malaria Day Apr 26, 2006
Another element of current optimism is the progress towards formulating a malaria vaccine. Clinical trials among children have shown promise, with the largest African trial of a malaria vaccine in Africa, conducted by GlaxoSmithKline Biologicals, the Hospital Clinic of the University of Barcelona and the Manhica Health Research Center in Mozambique, reducing the rate of infection by 29 percent and the incidence of severe malaria by 49 percent among 2000 children. (allAfrica.com)
GTC Biotherapeutics to Host First Quarter 2006 Earnings Call and... Apr 22, 2006
In addition to the ATryn(R) program, GTC is developing a recombinant human alpha-1 antitrypsin, a recombinant human albumin, a CD137 antibody to stimulate the immune system as a potential treatment for solid tumors, and a malaria vaccine. GTC also enters into partnering arrangements, or external programs, in which its technology is used to develop transgenic production of its partners' proprietary products, including both large-volume protein therapeutics as well as products that are difficult... (CNBC -- Research Alerts)
Potential vaccine developed for deadly leishmaniasis disease Apr 22, 2006
is working on one such malaria vaccine that is in late-stage preclinical trials. Other candidate vaccines against anthrax and tuberculosis are at an earlier stage of development. (EurekAlert!)
Malaria Parasite Impairs Key Immune System Cells Apr 17, 2006
(February 17, 1999) -- A team of researchers, including grantees of the National Institute of Allergy and Infectious Diseases, today reported positive results of research on a new, broad-based malaria vaccine. A paper. (Science Daily)
Turning Yellow Apr 10, 2006 Vaccine hope for prostate Feb 14, 2006 Prostate cancer drug hope Feb 13, 2006 Malaria vaccine 'close' Feb 13, 2006 Crossing the Gene Barrier Jan 10, 2006
Charles M. Rice, head of the Laboratory of Virology and Infectious Disease at Rockefeller, has shown in mice that a component of malaria vaccine inserted into YF17D elicited malaria-targeted T cells and gave the mice long-lasting protection against the infection. In similar experiments with mice and monkeys, Andino has used YF17D to deliver HIV antigens--immune-provoking bits of viral protein. (Scientific American)
China's home-made malaria vaccine to be tested on humans Mar 16, 2006
SHANGHAI, March 16 (Xinhuanet) -- A China-developed malaria vaccine will soon undergo clinical trials in Shanghai -- a move China hopes it will contribute to global prevention efforts of the deadly disease ... The trails will be funded by the worldwide non-profit fund PATH,and its Malaria Vaccine Initiative ... 9 malaria vaccine, developed by medical experts with the Shanghai No. 2 Medical College of the Chinese People's Liberation Army (PLA), is one of 20 new malaria vaccines around the world... (Xinhuanet, China)
The breakthrough, which follows the Queensland development of cervical cancer vaccine, comes as Queensland Institute of Medical Research scientists also begin human trials on a malaria vaccine. It has taken the Mater Medical Research Institute more than six years to develop the prostrate vaccine, which primes a patient's immune system to identify the cancer cells and destroy them. (Brisbane Courier Mail)
Queensland scientists will also today announce human clinical trials of a malaria vaccine. Animal studies with a vaccine from the Queensland Institute of Medical Research have shown it is possible to become immune to more than one malaria strain. (Melbourne Hearld Sun.au)
The Advertiser: Malaria vaccine 'close' [13feb06 ... Malaria vaccine 'close' By Roberta Mancuso 13feb06 ... "The current strategy to making the malaria vaccine is to find a single protein, like a silver bullet, and use that to immunise people to make an immune response which will protect against the entire organism," Prof Good said. (Advertiser Adelaide)
GTC has developed herds to produce other drugs, such as a malaria vaccine and a treatment to shrink solid tumors. Even though Meade is approaching the age when others might prefer golf courses to goat farms, he's too energized by the potential of transgenics to leave it behind. (BusinessWeek)
Back to FindHealthNews Home
©1998-2006 SurfWax, Inc.
All rights reserved. Patents pending.
Copyright SurfWax, Inc. 2006 |